Alnylam's Vutrisiran Shows Strong First-Line Efficacy in ATTR-CM Across Diverse Patient Groups

Event summary

  • Alnylam presented new HELIOS-B Phase 3 study data at Heart Failure 2026 showing vutrisiran's consistent clinical benefits across diverse ATTR-CM patient populations, including those with high disease burden.
  • Vutrisiran demonstrated significant reductions in all-cause mortality and recurrent cardiovascular events in patients with atrial fibrillation, representing 65% of the study population.
  • A pooled safety analysis of over 25,000 patient-years showed low rates of vitamin A deficiency-related adverse events comparable to placebo.
  • Alnylam announced the design of the DemonsTTRate study, a global, prospective, observational study expected to enroll over 2,000 ATTR-CM patients.

The big picture

Alnylam's data reinforces vutrisiran's potential as a foundational therapy for ATTR-CM, addressing a critical gap in treating a rapidly progressive, life-threatening disease. The consistent benefits across complex patient groups and the robust safety profile could accelerate its adoption as a first-line treatment. The upcoming DemonsTTRate study will be key in validating these findings in real-world settings, potentially expanding the drug's market reach.

What we're watching

Market Expansion
Whether Alnylam can leverage these results to expand vutrisiran's first-line use in ATTR-CM across broader patient populations.
Real-World Evidence
The pace at which the DemonsTTRate study generates longitudinal data that could further solidify vutrisiran's clinical profile.
Competitive Positioning
How these findings position vutrisiran against existing and emerging therapies for ATTR-CM.